Proof of Concept of the Ability of the Kinect to

Proof of Concept of the Ability of the Kinect to Quantify Upper
Extremity Function in Dystrophinopathy
March 14, 2013 · Natural History and Outcome Measures
Linda P Lowes, Lindsay N Alfano, Brent A Yetter, Lise Worthen-Chaudhari, William Hinchman, Jordan Savage, Patrick Samona,
Kevin M Flanigan, Jerry R Mendell
Lowes LP, Alfano LN, Yetter BA, Worthen-Chaudhari L, Hinchman W, Savage J, Samona P, Flanigan KM, Mendell JR. Proof of
Concept of the Ability of the Kinect to Quantify Upper Extremity Function in Dystrophinopathy. PLOS Currents Muscular
Dystrophy. 2013 Mar 14 . Edition 1. doi: 10.1371/currents.md.9ab5d872bbb944c6035c9f9bfd314ee2.
Abstract
Introduction: Individuals with dystrophinopathy lose upper extremity strength in proximal muscles followed by those more distal.
Current upper extremity evaluation tools fail to fully capture changes in upper extremity strength and function across the disease
spectrum as they tend to focus solely on distal ability. The Kinect by Microsoft is a gaming interface that can gather positional
information about an individual’s upper extremity movement which can be used to determine functional reaching volume,
velocity of movement, and rate of fatigue while playing an engaging video game. The purpose of this study was to determine the
feasibility of using the Kinect platform to assess upper extremity function in individuals with dystrophinopathy across the
spectrum of abilities. Methods: Investigators developed a proof-of-concept device, ACTIVE (Abilities Captured Through
Interactive Video Evaluation), to measure functional reaching volume, movement velocity, and rate of fatigue. Five subjects with
dystrophinopathy and 5 normal controls were tested using ACTIVE during one testing session. A single subject with
dystrophinopathy was simultaneously tested with ACTIVE and a marker-based motion analysis system to establish preliminary
validity of measurements. Results: ACTIVE proof-of-concept ranked the upper extremity abilities of subjects with
dystrophinopathy by Brooke score, and also differentiated them from performance of normal controls for the functional reaching
volume and velocity tests. Preliminary test-retest reliability of the ACTIVE for 2 sequential trials was excellent for functional
reaching volume (ICC=0.986, p<0.001) and velocity trials (ICC=0.963, p<0.001). Discussion: The data from our pilot study with
ACTIVE proof-of-concept demonstrates that newly available gaming technology has potential to be used to create a low-cost,
widely-accessible and functional upper extremity outcome measure for use with children and adults with dystrophinopathy.
Funding Statement
Funding for the development of the ACTIVE proof-of-concept device was provided by the Research Institute at Nationwide
Children’s Hospital Office of Technology Commercialization.
Introduction
Individuals with dystrophinopathy undergo progressive loss of muscle strength and function across the lifespan1,2 . This loss of
function impacts independence in ambulation, self-care, and other daily activities directly influencing quality of life3,4. For the
first time in decades there are potential treatments on the horizon for individuals with Duchenne muscular dystrophy (DMD)
through exon skipping, small molecules and gene therapy5. Although these trials are providing hope for patients with DMD for
the very first time, they are not accessible to all individuals with this disease. These experimental trials use timed walking as the
primary functional outcome measure due to ease of test administration, ability to quantify distance walked, and literature
investigating the reliability and validity of these walking outcomes6–8. Boys who cannot walk are therefore not eligible for
participation in these initial pivotal trials. The biggest obstacle to performing clinical trials that address function in the boys and
men who are non-ambulatory is the dearth of adequate, quantifiable, and sensitive upper extremity (UE) outcome measures to
capture changes over time9. This leaves an enormous unmet need for a large proportion of persons with neuromuscular
disease who can no longer walk; and therefore given delayed access to these potentially lifesaving drugs due to the lack of a
valid and reliable UE functional outcome measure.
Dystrophinopathy causes a characteristic loss of muscle strength in proximal muscles first followed by distal musculature over
time. Current outcome measures do not accurately measure changes in strength and function that occurs in individuals with
dystrophinopathy across the lifespan 10. There are many reasons for this. First, these outcomes, such as the Jebsen Taylor
Hand Function Test, 9 Hole Peg Test, Melbourne Assessment, were originally designed for other patient groups and do not
capture the unique weakness patterns found in dystrophinopathy 9,11–17. Despite the integral interdependence of both proximal
and distal muscles necessary for function, many current UE outcome measures typically focus on distal abilities alone or include
limited evaluation of anti-gravity movements requiring proximal muscle strength 9,10,14–16. Patient reported outcome measures
such as the Egan Klassifikation scale provide information regarding an individual’s overall level of functioning, but are too broad
PLOS Currents Muscular Dystrophy
1
to measure change in clinical trials 9,18,19. Lastly, many of these functional outcomes use an ordinal level Likert scale that limits
statistical analysis. A continuous scale outcome measure designed to measure full UE abilities over time in patients with
dystrophinopathy is in critical need at this time of ground-breaking clinical trials.
Video-based assessments have the potential to accurately collect data, removing some of the examiner-rater bias of existing
scales. The Microsoft Kinect is a controller-free gaming device interface that can document participant motion, including the full
UE from shoulder to hand. The Kinect is able to track participant motion using the imbedded infrared camera to record positional
data over time. Through the capture of participant motion, the Kinect has the potential to gather information related to functional
reaching volume (FRV), velocity of movement, and rate of fatigue. Functional reaching volume is the space within which a
person can interact with the environment around them 20–22. Measurement of this variable, would allow researchers to quantify
functional ability. A larger FRV would likely correlate with an increase in functional ability 20–22. Velocity of reaching is a second
component of UE function necessary for independence and is important because, if activity performance is too slow and
cumbersome, a caregiver will likely take over the task and an area of independence is lost 23. One final movement component
essential to independent function is the ability to sustain movement. The rate in which a person fatigues, or the rate in which
their velocity declines, is directly related to the amount of functional work or play that can be performed in a day24–26. A
person’s rate of fatigue dictates whether they can participate in leisure activities, attend school or hold a job 27. The Kinect
framework also has the potential to utilize gaming to increase participant motivation over time to reliably measure full UE
abilities.
In collaboration with a software development company we conducted a feasibility study to determine if the Kinect platform could
be used to create an UE outcome measure for dystrophinopathy. An assessment tool was developed to measure UE functional
reaching volume, velocity, and rate of fatigue and a small pilot study was completed to establish proof of concept.
Methods
This proof-of-concept called the ACTIVE (Ability Captured Through Interactive Video Evaluation) used the Microsoft Kinect for
Windows controller-free gaming interface to capture movement of the UE while a subject plays 2 custom-designed video games
(Figure 1). The Kinect relies on its built-in video camera and 3-dimensional (3D) depth sensors (an active-sensing depth camera
using structured light) to capture and record participant motion. The Kinect projects an infrared reference matrix that is offset by
and reflects off of the person in front of the system. This is then captured by a depth sensor to generate a high-resolution depth
map of each pixel allowing for tracking of movement. Current estimates of resolution at 2 meters from the Kinect system are 3
mm in the horizontal and vertical axes and 10 mm in depth 28.
Computations for creating the depth map were handled through the PrimeSense image processor chip embedded within the
Kinect device. The ACTIVE software calculated depth from disparity of the projected reference matrix to the captured offset
matrix. In addition to the depth sensor; the Kinect has an RGB (red, green, and blue) camera based on a complementary metaloxide semiconductor that delivers the three basic color components that can be combined to provide a full color image. Using
these data, the ACTIVE software calculated the centroid of a contrasting color sticker that had been placed on the subject’s
hand. Using a combination of the depth and color camera systems, the ACTIVE software measured participants’ functional
reaching volume, velocity of movement, and rate of fatigue.
To capture these variables, two basic games were created. ACTIVE’s FRV game used the Kinect’s 3D depth sensor to
determine the space or envelope through which a player reached during a virtual coloring game. The subject was encouraged to
reach as far as possible in every direction to fully paint the screen. ACTIVE calculated the total space contacted and reports that
volume in cubic milliliters. In the second game, ACTIVE measured UE reaching velocity (centimeters per second) and rate of
fatigue (percentage of decline) by using the RGB camera to determine the exact location of two yellow targets placed on a
tabletop. A blue dot was then placed on the subject’s hand and the game encouraged him to move his hand as quickly as
possible between the yellow targets before time ran out. Velocity data was captured up to 30 times per second during each trial.
From each of these velocity steps, ACTIVE calculated the minimum, maximum and average velocity of the trial. To determine
the player’s rate of fatigue, the average UE movement velocity is calculated for the first and second half of the trial. This method
was used to calculate the overall fatigue independently of speed. For example, a subject who moved very slowly would
obviously have a slow velocity, but might not show a substantial decrease in velocity from the beginning to the end of the game
trial; whereas another subject might start out quickly but could decline in speed substantially within the 30 seconds of a game
play test. By comparing the velocities produced within the first and second half of the game play period, the game summarized
any decline in velocity observed over time and reported that as fatigue.
Preliminary reliability and validity testing:
Informed consent was obtained from 5 non-ambulatory subjects with a dystrophinopathy (ages 9-36 years) and 5 adult control
subjects. The subjects with dystrophinopathy were classified based on their upper extremity abilities using the Brooke upper
extremity functional rating scale (Brooke)29. The Brooke scale was developed for clinical use in grading general UE function on
a 6 point scale, with larger values indicating less function. Each subject completed 3 trials of the FRV and velocity games using
each UE to evaluate preliminary reliability between trials. All trials were completed during one study session. Subjects also
PLOS Currents Muscular Dystrophy
2
completed the modified Borg ratings of perceived exertion scale (RPE)30–31. The modified Borg RPE rates how hard the person
feels they are working from a score of 6 (no exertion at all) to 20 (maximum exertion). The RPE score was used to compare the
subject’s perceived fatigue to the upper extremity fatigue calculated across trials using the Kinect device.
To evaluate validity of the ACTIVE, one non-ambulatory subject with dystrophinopathy was recorded by the Vicon passive
marker-based motion analysis system (MC) while he was simultaneously completing 3 trials of ACTIVE velocity test with each
upper extremity. In the MC lab, 8 cameras record passive reflection data from markers positioned over the acromion process
and on either side of the wrist to define the upper extremity. To enable three dimensional analyses of these data, a cluster of
three or more markers, consistent with the method proposed by Cappozzo and colleagues32, was placed on each relevant body
segment (hand, forearm, upper arm, torso) and also on the chair back for a total of approximately 37 markers. Markered data
were filtered (Butterworth dual pass, low pass, 6Hz) and the volume within which the arm moved was calculated as the convex
hull of all markers (cubic millimeters) in the Visual 3D analysis program. Velocity of the centroid of one reflective marker, placed
on the distal first metacarpal head, was calculated in Matlab as were mean velocities from the first and second half of each
game play test.
Ethics statement
This study was approved by the Institutional Review Board at the Research Institute at Nationwide Children’s Hospital. All
subjects provided written informed consent to participate.
Statistical analysis
Intraclass correlation coefficients were used to compare sequential trials of the assessments as well as comparing ACTIVE to
MC.
Results
Validity
Initial validity of the ACTIVE proof-of-concept is supported by its ability to accurately differentiate subjects based on their upper
extremity abilities. The ACTIVE discriminately ranked subjects with dystrophinopathy by Brooke scale score and also
differentiated them from normal controls (Figure 2) for both the functional reaching volume and velocity tests. Validation against
MC demonstrated the stability of the device, but not the absolute accuracy. Data captured simultaneously with the 2 systems
showed that the ACTIVE consistently overestimated the subject’s velocity (Mean 20.3% +/- 2.4) (Table 1).
Reliability
When the data are viewed graphically in Figure 2, a learning effect becomes apparent on both the FRV and the velocity test.
Preliminary test-retest reliability of the ACTIVE for 2 sequential trials (4 data points were from subjects with dystrophinopathy
and 9 data points were from adult healthy controls) was excellent for FRV (ICC=0.986, p<0.001). Similar results were seen with
the velocity data with excellent test-retest reliability (ICC=0.963, p<0.001).
Rate of fatigue
Fatigue was studied in a single subject with dystrophinopathy. RPE score increased as his rate of fatigue increased (Table 2).
Discussion
PLOS Currents Muscular Dystrophy
3
The data from our pilot study with the ACTIVE proof-of-concept device establishes the feasibility of using commercially available
gaming technology to create a low-cost, widely accessible, and functional outcome measure for use with children and adults
with upper extremity dysfunction across the spectrum of abilities. The cost associated with the Kinect SDK for Windows is under
$250, and the device can be purchased conveniently online or in most local retail stores. Our collaboration with a software
development company, allowed us to collect and analyze the information collected with the Kinect platform. This postprocessing can be completed by any mathematical or statistical department with knowledge regarding interpretation of the xyzcoordinate positional data output provided by the Kinect internal software. This platform has the potential to gather information
regarding movement breadth, patterns, speed, and changes in movement variables over time in a variety of conditions affecting
the upper extremity. Also, because the output can be analyzed post-examination, the outcome measure could collect any
variety of movement patterns of interest for each unique disease progression.
Our ACTIVE proof-of-concept development is novel in several ways. First, knowledge users and patient advocates contributed
to the development process. Those involved in the program design included persons with expertise in the clinical care and
disease process of individuals with muscular dystrophy, those with understanding of the Kinect platform and its capabilities,
personnel with knowledge of mathematical principles necessary to analyze data recorded, and patient advocates and
representatives with specific knowledge on the relevance of functional tasks on individual quality of life and independence.
Bringing all of these stakeholders together, allowed our team to produce a functional and engaging proof-of-concept with the
potential to measure clinically meaningful changes across the lifespan.
To improve upon existing methods to measure FRV, ACTIVE calculated the volume of space available to the participant during
the performance of tasks that require cognitive-somatic integration, such as wiping clean a table top or window or reaching for a
motivating target (e.g. food, drink of water). This method has the potential to better capture the extent to which the patient can
access his environment and better predict his ability to perform functional activities. Current assessments do not capture the
unique progression of weakness and loss of function found in dystrophinopathy as they were created for use in other diseases
and adopted for use in neuromuscular disease due to the absence of a gold standard. Many of these assessments focus solely
or primarily on distal abilities, and are thus incapable of detecting a decline in function until later in the progression of
dystrophinopathy 9101516. Individuals with DMD develop a wide range of compensatory movement patterns in an effort to
maintain distal function in the presence of proximal weakness, thereby forestalling functional decline until weakness progresses
beyond the point that these compensations suffice 33. These clinical tests of distal function are not capable of quantifying or
qualifying these compensatory movements throughout the non-ambulant period9. Our pilot study results indicated that the
ACTIVE proof-of-concept utilizing the Kinect video-based platform to capture movement data could distinguish between nonambulatory subjects with dystrophinopathy of differing abilities. Although there appeared to be an initial learning effect, subject
performance was consistent across trials within the same testing session. Our device incorporated movements that measured
both proximal and distal abilities in one engaging outcome measure.
Lastly, ACTIVE reported velocity and rate of fatigue, or rate of decline in velocity, of UE movement. As described above, velocity
of movement is an important component of an individual’s functional independence. Someone may be able to access a portion
of their FRV, but if it requires too much time or effort that area may not be utilized frequently. Similarly, if an FRV quadrant is
accessible, but induces fatigue quickly, a person may choose not to use that portion of their FRV readily. These variables have
implications for functional independence that can provide researchers or clinicians with a full picture of an individual’s change in
function over time. ACTIVE differentiated between subjects with dystrophinopathy of differing abilities by velocity of UE
movement. Again, test-retest reliability in our pilot study indicated that individual performance was consistent across trials within
the same testing session. Our preliminary data on a single patient suggests that the ACTIVE could provide a means for
quantifying a subject’s ability to sustain work. Studies of this modality in a larger cohort are underway.
The authors acknowledge that ACTIVE is currently a proof-of-concept and not yet ‘trial ready.’ The purpose of this pilot study
was to investigate the feasibility of this type of outcome measure in a population of non-ambulatory individuals with
dystrophinopathy. Development of this cutting edge technology is a dynamic process as changes and updates are added
immediately as new data are obtained. Future studies will include evaluation of UE abilities in a larger sample to examine
ACTIVE’s ability to detect more subtle changes in function versus our current comparison with the broad Brooke levels.
This current proof-of-concept is specifically focused on evaluating UE functional abilities in adolescents and adults with
dystrophinopathy. However, this platform has the potential to be used across the lifespan and could have software designed to
measure a variety of functional abilities. The engaging gaming aspect of ACTIVE has the potential to increase motivation and
understanding of testing directions. Currently participants were encouraged to ‘paint the screen.’ This simple task didn’t require
much direction and was somewhat intuitive. Further research is needed to determine the effect of cognitive impairments or
behavioral difficulties on cooperation during testing with ACTIVE.
Summary
This proof-of-concept pilot data demonstrates the feasibility of ACTIVE to capture reproducible upper extremity functional
reaching volume, movement velocity, and rate of UE fatigue in individuals with dystrophinopathy, and may discriminate among
disease severity when compared to functional rating scales. The adaptation of new gaming technology should allow
PLOS Currents Muscular Dystrophy
4
development of engaging, accurate, and low-cost assessments. This is timely given recent developments in the area of
Duchenne muscular dystrophy treatment, where trials are underway or planned for exon-skipping, stop codon read-through, and
gene therapies 34, but this technology also holds promise for the assessment of many other neurologic and musculoskeletal
disorders.
Competing Interests
Kevin M. Flanigan is an editor of PLOS Currents Muscular Dystrophy but was not involved in the evaluation of this article. The
authors have declared that no other competing interests exist.
References
1. Mendell JR, Province MA, Moxley RT 3rd, Griggs RC, Brooke MH, Fenichel GM, Miller JP, Kaiser KK, King W, Robison J.
Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls.
Arch Neurol. 1987 Aug;44(8):808-11. PubMed PMID:3115236.
2. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP, Province MA. Clinical investigation in Duchenne
dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve. 1983 Feb;6(2):91103. PubMed PMID:6343858.
3. Baiardini I, Minetti C, Bonifacino S, Porcu A, Klersy C, Petralia P, Balestracci S, Tarchino F, Parodi S, Canonica GW, Braido
F. Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol. 2011
Jun;26(6):707-13. PubMed PMID:21482750.
4. Bendixen RM, Senesac C, Lott DJ, Vandenborne K. Participation and quality of life in children with Duchenne muscular
dystrophy using the International Classification of Functioning, Disability, and Health. Health Qual Life Outcomes. 2012 May
22;10:43. PubMed PMID:22545870.
5. Rodino-Klapac LR, Mendell JR, Sahenk Z. Update on the treatment of duchenne muscular dystrophy. Curr Neurol Neurosci
Rep. 2013 Mar;13(3):332. PubMed PMID:23328943.
6. Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, Elfring G, Reha A, Barth J, McDonald CM. Percent-predicted 6minute walk distance in duchenne muscular dystrophy to account for maturational influences. PLoS Curr. 2012 Jan
25;4:RRN1297. PubMed PMID:22306689.
7. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L, Elfring GL, Reha A, Miller LL. The 6-minute walk
test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve. 2010 Dec;42(6):966-74. PubMed
PMID:21038378.
8. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL. The 6minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010 Apr;41(4):500-10. PubMed
PMID:19941337.
9. Mazzone ES, Vasco G, Palermo C, Bianco F, Galluccio C, Ricotti V, Castronovo AD, Mauro MS, Pane M, Mayhew A, Mercuri
E. A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. Dev Med Child Neurol.
2012 Oct;54(10):879-85. PubMed PMID:22713125.
10. Mattar FL, Sobreira C. Hand weakness in Duchenne muscular dystrophy and its relation to physical disability. Neuromuscul
Disord. 2008 Mar;18(3):193-8. PubMed PMID:18207403.
11. Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch
Phys Med Rehabil. 1969 Jun;50(6):311-9. PubMed PMID:5788487.
12. Smith YA, Hong E, Presson C. Normative and validation studies of the Nine-hole Peg Test with children. Percept Mot Skills.
2000 Jun;90(3 Pt 1):823-43. PubMed PMID:10883762.
13. Randall M, Carlin JB, Chondros P, Reddihough D. Reliability of the Melbourne assessment of unilateral upper limb function.
Dev Med Child Neurol. 2001 Nov;43(11):761-7. PubMed PMID:11730151.
14. Servais L, Deconinck N, Moraux A, Benali M, Canal A, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Desguerre I,
Maincent K, Themar-Noel C, Quijano-Roy S, Serari N, Voit T, Hogrel JY. Innovative methods to assess upper limb strength and
function in non-ambulant Duchenne patients. Neuromuscul Disord. 2013 Feb;23(2):139-48. PubMed PMID:23219352.
15. Svensson E, Häger-Ross C. Hand function in Charcot Marie Tooth: test retest reliability of some measurements. Clin
PLOS Currents Muscular Dystrophy
5
Rehabil. 2006 Oct;20(10):896-908. PubMed PMID:17008341.
16. Wagner MB, Vignos PJ Jr, Carlozzi C, Hull AL. Assessment of hand function in Duchenne muscular dystrophy. Arch Phys
Med Rehabil. 1993 Aug;74(8):801-4. PubMed PMID:8347064.
17. Poole JL, Burtner PA, Torres TA, McMullen CK, Markham A, Marcum ML, Anderson JB, Qualls C. Measuring dexterity in
children using the Nine-hole Peg Test. J Hand Ther. 2005 Jul-Sep;18(3):348-51. PubMed PMID:16059856.
18. Vandervelde L, Van den Bergh PY, Goemans N, Thonnard JL. ACTIVLIM: a Rasch-built measure of activity limitations in
children and adults with neuromuscular disorders. Neuromuscul Disord. 2007 Jun;17(6):459-69. PubMed PMID:17433675.
19. Lyager S, Steffensen B, Juhl B. Indicators of need for mechanical ventilation in Duchenne muscular dystrophy and spinal
muscular atrophy. Chest. 1995 Sep;108(3):779-85. PubMed PMID:7656633.
20. Robinson MA, Barton GJ, Lees A, Sett P. Analysis of tetraplegic reaching in their 3D workspace following posterior deltoidtriceps tendon transfer. Spinal Cord. 2010 Aug;48(8):619-27. PubMed PMID:20065989.
21. Kurillo G, Han JJ, Abresch RT, Nicorici A, Yan P, Bajcsy R. Development and application of stereo camera-based upper
extremity workspace evaluation in patients with neuromuscular diseases. PLoS One. 2012;7(9):e45341. PubMed
PMID:23028947.
22. Abdel-Malek K, Yang J, Brand R, Tanbour E. Towards understanding the workspace of human limbs. Ergonomics. 2004 Oct
22;47(13):1386-405. PubMed PMID:15513715.
23. Jansen M, de Groot IJ, van Alfen N, Geurts ACh. Physical training in boys with Duchenne Muscular Dystrophy: the protocol
of the No Use is Disuse study. BMC Pediatr. 2010 Aug 6;10:55. PubMed PMID:20691042.
24. Sveen ML, Jeppesen TD, Hauerslev S, Køber L, Krag TO, Vissing J. Endurance training improves fitness and strength in
patients with Becker muscular dystrophy. Brain. 2008 Nov;131(Pt 11):2824-31. PubMed PMID:18776212.
25. Abresch RT, Carter GT, Jensen MP, Kilmer DD. Assessment of pain and health-related quality of life in slowly progressive
neuromuscular disease. Am J Hosp Palliat Care. 2002 Jan-Feb;19(1):39-48. PubMed PMID:12173612.
26. Lou JS, Weiss MD, Carter GT. Assessment and management of fatigue in neuromuscular disease. Am J Hosp Palliat Care.
2010 Mar;27(2):145-57. PubMed PMID:20190203.
27. Parks NE, Eskes GA, Gubitz GJ, Reidy Y, Christian C, Phillips SJ. Fatigue impact scale demonstrates greater fatigue in
younger stroke survivors. Can J Neurol Sci. 2012 Sep;39(5):619-25. PubMed PMID:22931703.
28. Wong, W. How Microsoft's PrimeSense-based Kinect Really Works. 2011.
29. Lord JP, Portwood MM, Lieberman JS, Fowler WM Jr, Berck P. Upper extremity functional rating for patients with Duchenne
muscular dystrophy. Arch Phys Med Rehabil. 1987 Mar;68(3):151-4. PubMed PMID:3827555.
30. Borg GA. Perceived exertion. Exerc Sport Sci Rev. 1974;2:131-53. PubMed PMID:4466663.
31. Scherr J, Wolfarth B, Christle JW, Pressler A, Wagenpfeil S, Halle M. Associations between Borg's rating of perceived
exertion and physiological measures of exercise intensity. Eur J Appl Physiol. 2013 Jan;113(1):147-55. PubMed
PMID:22615009.
32. Cappozzo A, Cappello A, Della Croce U, Pensalfini F. Surface-marker cluster design criteria for 3-D bone movement
reconstruction. IEEE Trans Biomed Eng. 1997 Dec;44(12):1165-74. PubMed PMID:9401217.
33. Lord R, Hulme C. Perceptual judgments of normal and clumsy children. Dev Med Child Neurol. 1987 Apr;29(2):250-7.
PubMed PMID:3582795.
34. Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X,
Tremblay JP. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther. 2011
May;19(5):830-40. PubMed PMID:21468001.
PLOS Currents Muscular Dystrophy
6